Page last updated: 2024-10-27

fenofibrate and Abdominal Obesity

fenofibrate has been researched along with Abdominal Obesity in 2 studies

Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE

Research Excerpts

ExcerptRelevanceReference
"Fenofibrate is a peroxisome proliferator-activated receptor-α that has been clinically used to treat dyslipidemia and insulin resistance."5.19Fenofibrate increases serum vaspin by upregulating its expression in adipose tissue. ( Chen, M; Deng, D; Fang, Z; Hu, H; Luo, L; Wang, Y; Xu, M, 2014)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Shin, Y1
Lee, M1
Lee, D1
Jang, J1
Shin, SS1
Yoon, M1
Chen, M1
Deng, D1
Fang, Z1
Xu, M1
Hu, H1
Luo, L1
Wang, Y1

Trials

1 trial available for fenofibrate and Abdominal Obesity

ArticleYear
Fenofibrate increases serum vaspin by upregulating its expression in adipose tissue.
    Endocrine, 2014, Volume: 45, Issue:3

    Topics: 3T3-L1 Cells; Adipocytes; Adult; Animals; Disease Models, Animal; Dyslipidemias; Fenofibrate; Humans

2014

Other Studies

1 other study available for fenofibrate and Abdominal Obesity

ArticleYear
Fenofibrate Regulates Visceral Obesity and Nonalcoholic Steatohepatitis in Obese Female Ovariectomized C57BL/6J Mice.
    International journal of molecular sciences, 2021, Apr-01, Volume: 22, Issue:7

    Topics: Adipocytes; Animals; Diet, High-Fat; Drug Evaluation, Preclinical; Dyslipidemias; Fatty Liver; Femal

2021